A Multi-center, Un-controlled, Open-labeled Trial of the Long-term Safety of Lamazym Aftercare Treatment of Subjects With Alpha-Mannosidosis Whom Previously Participated in Lamazym Trials
Status: Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 03 Mar 2019
Price : $35 *
At a glance
- Drugs Velmanase alfa (Primary)
- Indications Alpha-Mannosidosis
- Focus Adverse reactions; Therapeutic Use
- Sponsors Chiesi Farmaceutici SpA; Zymenex A/S
- 21 Dec 2017 Planned End Date changed from 1 Dec 2018 to 1 Feb 2020.
- 21 Dec 2017 Planned primary completion date changed from 1 Dec 2018 to 1 Feb 2020.
- 01 Sep 2016 Planned End Date changed from 1 Feb 2017 to 1 Dec 2018.